Aktis Oncology filed for an initial public offering in the United States on Friday, as stock market listings from the biotech ...

Pfizer PFE expects a significant negative impact on revenues from the loss of exclusivity (“LOE”) of several of its key ...

Policy, precision medicine, and new ways of delivering therapeutics were popular topics in 2025 among readers of ...

Citius Oncology, Inc. (CTOR) has disclosed a new risk, in the Innovation / R&D category. Citius Oncology, Inc. faces material uncertainty in ...

ONCare Alliance supports community oncology practices with shared infrastructure, clinical programs, and research access, ...

The monotherapy trial suggested a confirmed overall-response rate of 46% and a disease-control rate of 93%. In combination with Keytruda, the confirmed overall-response rate was 71% and the ...

CG Oncology leads in NMIBC treatment with creto, strong efficacy data, and $2B+ revenue potential. Learn more about CGON ...

In this study, researchers sought to determine the impact of the FDA’s Accelerated Approval pathway among patients with solid tumors.

Patients are often stabilised for years on somatostatin analogues; however, progression eventually necessitates ...

If the past decade was about AI learning to see, read and summarize, the next one will be about AI learning to help.

The Oncology Institute, Inc. raised FY25 guidance to $500M revenue and expects positive Adj. EBITDA in Q4. Learn more about ...

Reliance Foundation Hospital inaugurates JEEVAN, a new oncology and dialysis wing dedicated to compassionate, patient-centric ...